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Expression of transforming growth factors beta-I,
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Summary We previously detected elevated transforming growth factor beta-1 (TGF-11) serum levels in patients with invasive bladder
carcinomas. In this study, we therefore investigated whether elevated serum levels correlate with enhanced TGF-1 expression in human
bladder tumours. mRNA levels of TGF-p1, -12 and -133 were reduced in bladder tumour tissue to 86%, 68% and 56%, respectively, of the
levels in normal urothelium. On the other hand, TGF-1l protein levels were found to be higher in superficial tumours (T7-T,) (mean level of
0.153 ng mg-1) and in invasiveTJ/3 tumours (mean level of 0.104 ng mg-') compared with normal urothelium (mean level of 0.065 ng mg-').
Invasive T4 tumours, however, contained only low amounts of TGF-1l (mean level of 0.02 ng mg-'). Neither in mean nor in individual patients
were serum and tissue TGF-1 levels correlated with each other. Cell culture experiments on primary bladder cells revealed a 57% decrease
in TGF-13l mRNA levels in tumour compared with normal epithelial cells. Tumour epithelial cells contained about two times higher levels of
TGF-P2 and TGF-P3 mRNA than normal epithelial cells. Fibroblasts expressed about the same amount of TGF-1l or TGF-,B2 as epithelial
cells. Yet, fibroblasts released only 19% and 13% ofthe amount secreted by tumourepithelial cells into the supernatant. TGF-P3, on the other
hand, was expressed by fibroblasts with higher levels than by epithelial cells. TGF-,1l was the predominent isoform in bladdertissue and cells
at protein as well as on mRNA levels indicating thatTGFs-P2 and -13 are of minor importance in bladder cancer. In summary, there is a lack
of correlation between TGF-P serum levels and TGF-1 expression in tumour tissue in bladder cancer.
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Transforming growth factors-1 (TGF-P) are a family ofmultifunc-
tional homodimeric polypeptides. Three different isoforms of
TGF-,B have been found in mammalian cells, termed TGF-11, -12
and -133. The mature 25-kDa peptides of all isoforms are struc-
turally and functionally similar (Roberts and Sporn, 1990),
although their regulation of secretion is distinct. TGF-,B1 is
secreted from most cells as a 225-kDa latent complex. It is
assumed thatTGF-P2 and-P3 are also synthesized as latent forms;
however, detailed knowledge about the structures of these
complexes is lacking (Brown et al, 1990). Activation of latent
TGF-1 by acidification or, more likely, by certain proteases, like
plasmin or cathepsin, play a critical role in the bioavailability of
TGF-,B (Lyons et al, 1988).
TGF-1 was regarded as a negative growth regulator because of
its potent anti-proliferative effects on many cell types, such as
endothelial and epithelial cells and various cell types of
haematopoietic origin in vitro (Roberts and Sporn, 1990). In
contrast, overexpression ofTGF-P1 has been described in several
tumours in vivo (Gorsch etal, 1992; Thompson et al, 1992; Steiner
et al, 1994) and has also been associated with tumour progression
and metastasis (Weidner et al, 1991; Gajdusek et al, 1993). The
advantageous effect of this increased TGF-1 synthesis on tumour
growth is probably caused by autocrine or paracrine activities
resulting in increased cell matrix interactions, inhibited immune
surveillance or increased angiogenic activity (Kekow et al, 1990;
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Yang and Moses, 1990; Kehrl, 1991). It has been suggested that in
most cases malignant epithelial cell lines have lost their respon-
siveness to the inhibiting activity ofTGF-1 (Chang et al, 1993).
In the course of investigations about the role of TGF-1 as a
potential tumour-promoting factor, elevated TGF-1I plasmalevels
have been detected in patients with invasive prostate cancer
(Ivanovic et al, 1995). In a similar study, we previously found
significantly elevated TGF-,B1 serum levels in patients with inva-
sivebladdercarcinomas (Ederetal, 1996). Inthe present study, we
investigated whether those elevated TGF-1 serum levels correlate
with increased TGF-,B expression in bladder tumour tissue and
whether isoforms differ in theirrespective expression. In addition,
we cultured primary epithelial and fibroblast urothelial cells in
order to study the importance ofthe stromal part in TGF-f expres-
sion and secretion.
MATERIALS AND METHODS
Acid-ethanol extraction of TGF-,1l from bladder tissue
We investigated tissue specimens from 23 patients with transi-
tional cell carcinoma (TCC) and compared them with a group of
22 samples from normal bladder urothelium. Tumour specimens
comprised nine superficial (Ta, Cis, TI) and 14 invasive tumours
(T2-T4). Normal bladder urothelium was dissected from histologi-
cally proven non-malignant areas during radical cystectomy.
Tumour samples were taken either during transurethral resection
or during radical cystectomy. All samples were immediately
frozen in liquid nitrogen. The extraction procedure as described by
Roberts et al (1983) was applied in a slightly modified form. The
tissue was minced and incubated in a solution of93% ethanol and
0.23 M hydrochloric acid with gentle overnight shaking at 4°C.
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Figure 1 Primary bladder cells were cultured as described in Materials and methods. Epithelial cells were grown in a serum-free medium (A). Fibroblasts,
grown in a medium supplemented with 10% FCS, depicted.the typical growth morphology pattern (B). Both cell types were differentiated not only by light
microscopy but also by immunocytochemistry. Epithelial cells were stained with anti-cytokeratin 8-18+19 antibody (C), whereas fibroblasts showed no reaction
with the same antibody (D)
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Figure 2 Using RT-PCR, we investigated mRNA levels of TGF-,B1, -,B2 and -
f3 in 16 tissue samples derived from human bladder tumours of different
stages (Ta-T4) and grades (G1-G3) (numbers 10-25) and compared them
with nine tissue samples from normal urothelium (numbers 1-9). mRNA
levels are indicated as a ratio of TGF-f to GAPDH. Mean values are
indicated as horizontal lines
After centrifugation, the supernatant was precipitated with two
volumes of ethanol (95%) and four volumes ofdiethylether for 48
at -200C. The resulting precipitate was collected by centrifugation
and resuspended in phosphate-buffered saline (PBS).
TGF-B1 values were measured by enzyme-linked immunosor-
bent assay (ELISA; Genzyme) and expressed in ng TGF-P1 mg-'
protein (ng mg-'). The protein content of the samples was deter-
mined according to the method ofBradford (1976).
Semi-quantitative polymerase chain reaction (PCR)
Total RNA was isolated from frozen tissues or cells using a guani-
dinium thiocyanate-acid phenol-chloroform (pH 4.0) extraction
method. Samples were precipitated with isopropanol, washed with
70% ethanol, dried, dissolved in protease K buffer (50 mM Tris, 20
mM EDTA, 100 mM Sodium chloride and 1% sodium dodecyl
sulphate; pH 7.5) and treated with protease K (200 gg ml-')
(Sigma-Aldrich, Vienna, Austria) at 55°C for 15 min. Thereafter,
the phenol-chloroform extraction procedure was repeated. Finally,
RNA was precipitated by isopropanol, washed twice with 70%
ethanol, dried and redissolved in diethylpyrocarbonate (DEPC)-
treated water. The amount of RNA was determined by measuring
the absorbance at 260 nm.
Reverse transcription was performed for 8 min at 20°C, 8 min at
25°C and 30 min at 42'C (four cycles) on 500 ng ofRNA in 40 ,l
containing finnzyme buffer [20 mm, potassium phosphate pH 7.2,
0.2 mm dithiothreitol (DTT), 0.02% Triton X-100, 5% glycerol],
0.5 mM dNTPs, 200 pmol N6-primers, 0.1% P-mercaptoethanol,
0.1 mg ml-' bovine serum albumin (Pharmacia, Vienna, Austria),
39 units ribonuclease inhibitor (Promega) and 10 units finnzyme
AMV reverse transcriptase (Biotrade, Margaritella, Vienna,
Austria).
PCR was performed with 2 pl of cDNA (diluted in water in
order to guarantee a quantitation of PCR fragments in the expo-
nential phase ofthe reaction) in a final volume of50 plcontaining
buffer [2 mM Tris-HCl, pH 7.4, 0.01 mM EDTA, 0.1 mM DTT, 10
mm potassium chloride, 0.01% Triton X-100, 16 ,ug ml-' bovine
serum albumin (BSA), 5% glycerol], 0.2 mm dNTPs, 0.62 units
Dyna-Zyme polymerase (Biotrade) and 0.25 gM of each primer.
Primers were synthesized on a 381A DNA Synthesizer (Applied
Biosystems, Vienna, Austria): glyceraldehyde-3 phosphate
dehydrogenase (GAPDH) was used as an internal control: 5'-
CACCACCATGGAGAAGGCTGG-3' (GAPDH 365) and 5'-
GTCTAGCTCAGGGATGACCTTG-3' (GAPDH 735as*);
TGF-f 1: 5'-AAGTGGATCC ACGAGCCCAA-3' (TGF-01) and
5'-GCTGCACTTGCAGGAGCGCAC-3' (TGF-plas*); TGF-
P2: 5'-AAATGGATACACGAACCCCAA-3' (TGF-,2) and
5'-GCTGCATTTGCAAGACTTTAC-3' (TGF-,2as*); TGF-13:
5'-AAGTGGGTCCATGAACCTAA-3' (TGF-33) and 5'-GCTA-
CATTTACAAGACTTCAC-3' (TGF-,3as*). Antisense primers
were fluorescence labelled at the 5' end as indicated by an asterisk.
Synthesis was performed on a thermocycler 60 (Bio med) with 20
s at94'C, 15 s at96°C, 1 min at 55°C and 30 s at73°C (34 cycles).
Afterwards, TGF-[B (1 pl) and GAPDH (1 gl) samples were mixed
with 2.5 pl of formamide and denatured at 90°C for 2 min. DNA
fragments were separated electrophoretically in a 6% polyacry-
lamide gel using the 370A DNA Sequencer (Applied Biosystems).
Fluorescence was measured and quantitated using 672A Software
1.2 (Applied Biosystems). Amounts of TGF-P mRNA were
normalized against the corresponding amounts of GAPDH
mRNA, which is unaffected by TGF-,1 (Edwards et al, 1985;
Norgaard et al, 1996). Results are presented as TGF-, - GAPDH
ratio. All measurements were performed at least twice.
Culture of primary bladder cells
Primary culture
Primary cell cultures were established from fresh tissue specimens
taken at transurethral resection or radical cystectomy. The tissue
was minced into little pieces. The obtained tissue pieces were
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Figure 3 After acid-ethanol extraction, TGF-j31 protein levels were
determined in tissue specimens from 23 bladder cancer patients and 22
specimens from normal urothelium. The histogram shows TGF-P1 values in
ng mg-' protein with mean values indicated as horizontal lines. Tumour
specimens were divided into groups of different tumour stages: superficial
tumoursTa-T,; invasive tumours T2-T3; and invasive T4-tumours
allowed to adhere to the plastic surface of a 25-cm2 culture flask
(Costar) and gently covered with Earl's modified Eagle medium
(EMEM) supplemented with 20% fetal calf serum (FCS), 1% of a
non-essential amino acid solution (Biological Industries), trans-
ferrin (1 jg ml-'), insulin (1 jig ml-') and penicillin/streptomycin
(120 IU ml', 120 jig ml-'). After 2-7 days, when cells began to
grow out of the tissue pieces, cultures were incubated in different
culture media in order to split epithelial cells and fibroblasts
respectively.
Culture ofepithelial cells
For the culture of epithelial cells, we used a serum-free MCDB-
153 medium (Sigma) supplemented with 1% of a solution of non-
essential amino acids (Biological Industries), epidermal growth
factor (EGF; 5 ng ml-'); Life Technologies, Gibco), bovine pitu-
itary extracts (30 jig ml-'; Life Technologies, Gibco), 0.2% bovine
serum albumin (Behring, Vienna, Austria), transferrin (10 jg
ml-'), insulin (1 jig ml-') and penicillin/streptomycin (120 IU ml-',
120 jg ml-'). Figure IA depicts a culture of primary bladder
epithelial cells.
Culture offibroblast cells
Fibroblasts were cultured in EMEM supplemented with 10% FCS,
a 1% solution ofnon-essential amino acids (Biological Industries)
and penicillin/streptomycin (120 IU ml-', 120 jig ml-'). Figure lB
shows a culture ofprimary fibroblast cells.
Epithelial cells and fibroblasts were differentiated by both light
microscopy, according to the typical growth morphology, and
immunocytochemistry, investigating the expression ofcytokeratin
8+18+19 (Monosan). Figure IC and D outline cytokeratin expres-
sion in epithelial and fibroblast cells respectively.
Collection ofcellpellets andculture supernatants
Cells were harvested with trypsin/EDTA (0.05%, 0.01%),
centrifuged at 8000 r.p.m. for 5 min and shock frozen in liquid
nitrogen. Cell culture supermatants were taken from 72 h condi-
tioned media, centrifuged to remove cell debris and stored at
-20°C. The amount of TGF-4 was corrected by the number of
cells. Values are presented in ng 10- cells. In order to avoid false-
positive results, TGF-. content of unconditioned media was
subtracted from the values measured in cell-conditioned media.
We used standard media as described above. EMEM that was used
for cultivation of fibroblasts contained 1.3 ng ml- TGF-1 and
0.06 pg ml-' TGF-P2, whereas the serum-free MCDB-153, used
for cultivation of epithelial cells, contained only 0.06 ng ml'
TGF-B1 and 0.01 pg ml-' TGF-,2.
Enzyme-linked immunosorbent assay (ELISA)
TGF-f1 and TGF-132 ELISAs (Genzyme and R&D Systems
respectively) were performed according to the manufacturer's
instructions. Since only active forms of TGF-P1 and -42 can be
recognized by the antibodies used in the kits, all samples except
those received by acid-ethanol extraction were activated by acidi-
fication as described previously (Eder et al, 1996).
Statistical analysis
Probability values were calculated by Kruskal-Wallis and
Mann-Whitney U-tests. P-values < 0.05 were taken as statistically
significant.
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Figure 5 mRNA levels of TGF-,B1, -P2 and -P3 were determined in a panel of
different human primary bladder cell lines. Epithelial cells derived from normal
urothelium (BNF) and tumour epithelial cells (BCE) were grown in a special
serum-free medium as described in Materials and methods. Fibroblasts
derived from normal urothelium (BNE) and tumour-derived fibroblasts (BCF)
were cultured in EMEM supplemented with 10% fetal calf serum. mRNA
levels were quantitated by RT-PCR and indicated as TGF-,B-GAPDH. Mean
values are indicated as horizontal lines
RESULTS
Expression of mRNA ofTGF-,31,-12 and-13 in human
bladder tissue specimens
Using semi-quantitative PCR, we compared expression ofTGF-131, -
132 and -,B3 mRNA in 16 bladder tumourtissue specimens with those
in nine samples from normal urothelium. Results are summarized in
Figure 2. In normal urothelium, all three TGF-ps were expressed.
TGF-I1 mRNA was also present in all 16 tumour samples. On the
contrary, TGF-,2 mRNA was only found in 11 and TGF-,3 -
mRNA only in 12 tumour samples. TGF-0I expression with a
median TGF-,1 - GAPDH ratio of 0.218 was reduced in tumour
tissue compared with normal urothelium with a median TGF-P1 -
GAPDH ratio of 0.254. Similarly, TGF-P2 and TGF-,B3 mRNA
levels were lower in tumour tissue (TGF-02 = 0.038; TGF-13 =
0.038) than in normal urothelium (TGF-P2 = 0.054; TGF-[3 =
0.066). Because of the strong variability within the different tissue
samples, statistical analysis did not reveal any significant difference
in mRNA expression between normal and tumourtissues. The sepa-
ration of tumour samples into different tumour stages showed that
superficial Ta tumours expressed slightly lower amounts of TGF-[B
mRNAs than invasive tumours. However, there was no significant
difference between superficial and invasive tumours.
TGF-p1 protein levels in human bladder tissue
specimens
Tissue specimens were extracted by acid-ethanol. The amounts of
TGF-i1 were measured by ELISA and related to total protein in
the extracts. As shown in Figure 3, TGF-f1 protein levels were
significantly higher in superficial tumours (Ta9 TI) with 0.153 ng
mg-' (n = 9) than in normal urothelium, which contained only
0.065 ng mg-' (n = 22) (P = 0.01). Similarly, invasive T2-T3
tumours had increasedTGF-P1 protein levels of0.104 ng mg-' (n
= 11). However, the difference to normal controls and superficial
tumours failed to reach statistical significance. Invasive T4
tumours contained significantly lower TGF-P1 protein levels of
0.02 ng mg-' (n = 3) than superficial (P = 0.03) and invasive T/T3
tumours (P = 0.01) respectively. TGF-,1 levels of T4 tumours
were also reduced compared with normal urothelium, but differ-
ences were not statistically significant (P = 0.15).
TGF-01 protein levels were higher in G1/G2 tumours (n = 8)
than in poorly differentiated G3 tumours (n = 15) (0.140 ng mg-'
and 0.098 ng mg-' respectively) (data not shown). Differences
were not statistically significant.
Correlation of TGF-,1 levels between serum and tissue
specimens in individual patients
We investigated whether there is a correlation between preopera-
tive serum TGF-f1 levels and the amount of TGF-f1 in tumour
tissue samples from the same patient. However, we could not find
any correlation (r = 0.09) (Figure 4).
Expression of mRNA ofTGF-31, -f2 and-P3 in different
bladder cells
We further investigated expression ofthe three TGF-f isoforms in
various human primary bladder cells derived from normal urothe-
lium as well as from bladder tumours of different stages (T,-T4)
(Figure 5). Epithelial cells and fibroblasts were separated by selec-
tive culture conditions as described in Materials and methods.
TGF-[I was expressed in all 23 cell strains examined. Normal
epithelial cells (n = 5) contained higher TGF-01 mRNA levels
with a median TGF-,1 - GAPDH ratio of 0.510 compared with
tumour epithelial cells (n = 7), which had a median TGF-01 -
GAPDH ratio of 0.291. However, the difference was not statisti-
cally significant. In general, TGF-,1 mRNA levels were higher
than both TGF-,2 andTGF-P3.
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mRNA levels (TGF-13 - GAPDH ratio = 0.021) than epithelial
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Figure 6 The amount ofTGF-p1 and -f2 in supernatants from human
primary bladder cells was measured by immunoassays. Epithelial cells
derived from tumour tissue (BCE) were subdivided into two groups, namely
cells derived from superficial (Ta-Tl) and from invasive tumours (T2-T4).
Moreover, supernatants from normal bladder epithelial cells (BNE), normal
fibroblast (BNF) and tumour-derived fibroblasts (BCF) were investigated.
Mean values are indicated as horizontal lines
TGF-[2, as well as TGF-[33, mRNA levels were higher in
tumour epithelial cells (n = 7) (TGF-[2 - GAPDH ratio = 0.053;
TGF-[3 - GAPDH ratio = 0.005) compared with normal epithelial
cells (n = 5) (TGF-[2) - GAPDH ratio = 0.031; TGF-,3 -
GAPDH ratio = 0.003). However, differences were not statistically
significant. TGF-[3 expression was very weak. mRNA ofTGF-[33
was found in only 15 out of23 cell strains.
Amount of TGF-f1 and TGF-[B2 in cell-conditioned
media
Using immunoassays, we evaluated TGF-[B1 and TGF-12 levels in
72 h-conditioned media of several primary bladder cells. Both
TGF-[1 and TGF-P2 could only be measured in acid-activated
cell culture supernatants (data not shown). This suggests that TGF-
P was mostly present in its latent form, as only active TGF-[ can
be detected by the immunoassays used in this study. Results are
presented in Figure 6.
Epithelial cells (BCE) derived from invasive tumours (T2 - T4, n
= 4) secreted slightly higher TGF-f1 levels of 4.23 ng 10-i cells
than epithelial cells derived from superficial tumours (Ta-TI, n =
7) (3.79 ng TGF-j1 10-5 cells). However, there was no significant
difference from normal epithelial cells (BNE), whose conditioned
media contained 3.74 ng TGF-[1 10- cells (n = 7).
Compared with epithelial cells, 0.75 ngTGF-[3 10-5 cells and
0.74 ngTGF-[Bl 105 cells were detected in supematants of
normal (BNF, n = 7) and tumour-derived fibroblasts (BCF, n = 10)
respectively.
Epithelial cells derived from superficial (n = 3) and invasive
(n = 2) tumours secreted higher amounts of TGF-[B2 (0.8 ng 10-5
cells) than normal epithelial cells (n = 2) in whose supernatants no
TGF-[2 was present. Only very low amounts of 0.08 ng TGF-[B2
10-5cells (n = 4) were found in supernatants from tumour-derived
fibroblasts. Amounts of TGF-1I in cell culture supernatants were
generally higher than those ofTGF-[B2.
DISCUSSION
Overexpression of TGF-[B1 has been commonly associated with
prostate (Thompson et al, 1992), breast and renal cancer (Gomella
et al. 1989, Coombes et al, 1990). In a previous study, we therefore
determined TGF-1I in sera from bladder cancer patients. TGF-[1
was found to be significantly elevated in sera from patients with
invasive bladder cancer (T2-T4) compared with serum levels from
patients with superficial tumours (Ta-T,) and normal control
subjects (Eder et al, 1996).
In this study, we were interested in whether elevated TGF-[
serum levels correlate with increased TGF-[ expression in bladder
tumours. However, we found reduced expression of mRNA of all
three TGF-[ isoforms, TGF-[B1, -[2 and -[3, in bladder tumour
samples compared with normal urothelium. There was neither a
correlation ofTGF-[ mRNA expression with tumour stages (Ta-T4)
nor with tumour grades (G1-G3). These results were somehow
unexpected, considering the increased serum levels in bladder
cancer patients. On the other hand, reduced TGF-[1 mRNA has
already been demonstrated in high-grade human bladder tumours
(Coombs et al, 1993; Miyamoto et al, 1995).
Investigating TGF-[1 protein levels in bladder tissue, we found
TGF-31 elevated significantly in superficial forms of bladder
cancer (Ta-T,) and moderately in invasive bladder carcinomas of
stages T2 and T3 compared with normal urothelium. By contrast,
TGF-[B1 protein levels were significantly decreased in invasive T4
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1758 IE Ederetal
A
15 -
0
0
0 CancerResearch Campaign 1997TGF-,B expression in bladdercarcinoma 1759
tumours. Similarly,TGF-01 levels were lower in poorly differenti-
ated in comparison with well and moderately differentiated
tumours. It is striking that TGF-P1 protein levels in tumour tissue
are in inverse proportion to serum levels. High TGF-[1 serum
levels in patients with invasive bladdercarcinomas correlate with a
small increase or a significant decrease ofprotein levels in T2-T3
and T4 tumour tissue, respectively, whereas low TGF-f1 serum
levels in patients with superficial bladder tumours correlate with a
significantly elevated protein level in tumour tissue. One can
assume that accumulation ofTGF-P in superficial tumours slows
down tumour progression through its growth-suppressive effects
as supposed by Miyamoto et al (1995). An explanation for the
small increase or decrease, respectively, in invasive tumours may
be that T4 tumours and, to a lesser extent, also T2 and T3 tumours
immediately release TGF-P into the surrounding tissue and the
circulation in order to exhibit immune suppression and stimulate
metastatic spread, whereas in the superficial tumours, TGF-1 is
accumulated in the tumour. Efficient access to the circulation is
enabled by the extended vascularization ofinvasive tumours.
Comparison of TGF-P serum and tumour levels of individual
patients also revealed no direct correlation with each other, indi-
cating that the expression level in the tissue is not crucial for the
final serum concentration. Other parameters, such as release rate,
blood supply of the tumour and tumour mass, are obviously more
important.
In the tissue samples we investigated, there was also no correla-
tion between mRNA and protein levels. This finding is in accor-
dance with previous studies, which already indicated that there is
no evidence for a direct correlation between TGF-i1 protein and
mRNA levels. Similar discrepancies have already been described
in the mouse embryo (Pelton et al, 1991). Differential expression
seems to be caused by post-transcriptional regulation ofexpression
through a 5' untranslated sequence in theTGF-0 mRNA (Kehrl et
al, 1986; Kim et al, 1992). On the basis ofourresults, we conclude
that neither mRNA nor protein levels found in tumour tissue
provide a conclusive explanation for increased TGF-11 levels in
the serum ofpatients with invasive bladder cancer.
An important question is whether the stromal part ofthe tumour
plays an important role inTGF-P production. It is well established
that the TGF-fs are secreted proteins; thus, certain cells may
synthesize and releaseTGF-P into the extracellular matrix ofadja-
cent cells that have the potential to respond. Both autocrine and
paracrine factors, which are produced by epithelial and stromal
cells, may play an important role in the local growth control, since
it is known that epithelium loses its growth capacity when sepa-
rated from the stroma (Kooistra et al, 1995). Some malignant
tumours may use TGF-f released from their environment for
enhancing their invasiveness and metastatic behaviour, while at
the same time being resistant to the growth-suppressive effect of
TGF-0. Exposure of tumour cells to exogenous TGF-f has been
shown to stimulate tumour cell invasion in vivo and metastatic
potential in vitro (Welch et al, 1990). In order to investigate the
contribution of different cell types to protein levels in the tissue,
we cultured human primary bladder cells separating epithelial
from fibroblast cells by different culture conditions.
Our measurements in samples ofcultured primary cells revealed
remarkable differences among the TGF-P isoforms concerning
their expression and secretion. TGF-P1 mRNA was expressed in
lower levels in tumour-derived compared with normal epithelial
cells, whereas TGF-u1 protein secretion into the culture medium
was almost equal between these two cell types. On the other hand,
TGF-P2 and TGF-P3 mRNAs were found to be slightly higher
expressed in tumour epithelial cells than in normal epithelial cells.
Accordingly, higher amounts ofTGF-132 were found in cell culture
supematants of tumour-derived compared with normal epithelial
cells. Considering that the absolute amounts of secreted TGF-P2
are about one-tenth ofthe amount of secretedTGF-p1, the differ-
ences inTGF-P32 release are probably ofminor importance.
In cultured fibroblasts, about the same amount of TGF-0
mRNAs as in epithelial cells as measured. This points out the
important role of the interaction between epithelium and stroma,
andlets us suppose thatfibroblasts would also secrete considerable
amounts of TGF-i. Yet, unexpectedly, fibroblasts released only
small amounts ofTGF-01 and TGF-P2 into the supematant. This
may be the result of a lower efficiency of translation of TGF-4
mRNA in fibroblasts, but it is also possible that a great part ofthe
produced TGF-P is immediately exhausted by the cells in culture
as a result ofautocrine stimulation.
In summary TGF-j is assumed to be overexpressed in superfl-
cial bladder cancer compared with invasive forms of bladder
cancer, indicating that expression is inversely correlated with
TGF-0 serum levels. Additionally, cell culture experiments
revealed that stromal cells play a role in TGF-3 production. Co-
cultures ofepithelial andfibroblast cells shouldbring further infor-
mation about the interaction between epithelium and stroma.
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